A Guide to Phase 1 Clinical Trial Designs
Different designs used in Phase 1 Clinical Trials suit certain study types to determine the safety, tolerability and pharmacokinetics (PK) of new compounds
Different designs used in Phase 1 Clinical Trials suit certain study types to determine the safety, tolerability and pharmacokinetics (PK) of new compounds
This article looks at the evaluation of three methods assessing an early-phase equivalence in biosimilars for Rheumatoid Arthritis treatments.
Learn more about the recent trends in biosimilar development, the FDA guidance on biosimilars, and how clinical trial designs need to adapt accordingly
Quanticate's latest blog explores generating CDISC Compliant PK Workflows as part of Pharmacokinetic Analyses.
This recent blog by Quanticate examines Pharmacokinetic Considerations when comparing Biosimilarities